HCL, Saila launch Panax Finder

NEW DELHI: HCL Technologies Ltd. and Saila Systems Inc, Japan, today

announced the launch of Panax Finder, a statistical analysis software

package, which can be used by Pharmaceutical companies in the drug discovery

process.

Japan-based Saila provides a range of services from software requirement analysis to systems supports jointly. This software will help pharmaceutical companies to identify the properties of the drug and predict its efficiency even before its synthesis, thereby gaining tremendously on time.

Panax Finder is an evolutionary, user friendly tool, which reduces the labor

intensive approach thereby saving thousands of dollars and years by

utilizing 3D Quantitative Structure Activity Relationship (QSAR) to guide

the chemical synthesis.

The development of robust computational techniques to support drug creation

is of paramount importance if the pharmaceutical industry is focused to

reduce the overall costs of drug development and bring more medicines to

market faster.

Commenting on the launch, Pradep Nair, vice president & head - Life Sciences

Practice, HCL, New Jersey, USA said, "With the increasing maturity and

complexity in IT environments today we felt the need to provide our

customers a tool that would reduce time inefficiency in drug discovery

caused due to multitude of possibilities in which compounds can combine and

synthesize and help them in saving cost."

Panax Finder facilitates generating reliable 3D QSAR model to provide

estimate of the relationship between the 3D molecule structures and their

activities in a series of drugs by adopting the efficient Voronoi polyhedral

decomposition algorithm and Support Vector Machines (SVM). The results

obtained by SVM have high accuracy in many applications and Panax Finder is

the first product to apply this method for 3DQSAR.